Hematology News

Patients with anaplastic lymphoma kinase-mutant non-small cell lung cancer exhibited considerably higher risk for thromboembolism than those with EGFR-mutant or wild-type disease, study results showed.

Among Black adults, those with sickle cell trait or disease had a higher likelihood of developing AKI compared with those who had a normal hemoglobin phenotype, according to a study.

Pegcetacoplan led to greater improvements in hemoglobin compared with eculizumab among patients with paroxysmal nocturnal hemoglobinuria, according to results of the phase 3 PEGASUS study published in The New England Journal of Medicine.

The novel gene therapy BAX 335 did not induce sustained factor IX expression among patients with hemophilia B, according to an interim analysis of a phase 1/phase 2 dose-escalation study published in Blood.

ASH awarded funding to 19 early-career investigators to support resumption of research paused due to the COVID-19 pandemic.

The influence of blood group on COVID-19 susceptibility and severity has been studied extensively since the start of the pandemic, with inconsistent results.

The NIH announced that it is ending a clinical trial evaluating the safety and effectiveness of COVID-19 convalescent plasma in ED patients with mild to moderate symptoms.

Patients with sickle cell disease-related kidney failure experienced similar reductions in mortality following transplantation as those whose kidney failure stemmed from other causes, according to researchers from Johns Hopkins.

Long-term follow-up data showed betibeglogene autotemcel to be a safe and efficacious treatment for patients with transfusion-dependent beta-thalassemia, according to study results presented at TCT Meetings Digital Experience.

Gene therapy developer bluebird bio suspended clinical trials using its LentiGlobin product for sickle cell disease due to reported cases of hematologic malignancies among patients who received the treatment.